Globus Medical (GMED) director receives 15,000 stock options at $94.15

Q: What insider activity did Globus Medical (GMED) report for Stephen T. Zarrilli?

Globus Medical reported that director Stephen T. Zarrilli was granted a stock option for 15,000 shares of Class A common stock on January 21, 2026 .

Q: What is the exercise price of the new Globus Medical (GMED) stock options?

The granted stock options have an exercise price of $94.15 per share for Class A common stock.

Q: When do Stephen T. Zarrilli’s Globus Medical (GMED) options vest and expire?

The options granted on January 21, 2026 will vest on January 1, 2027 and expire on January 21, 2036 .

Q: Is the Globus Medical (GMED) option grant reported as directly or indirectly owned?

The Form 4 shows the 15,000 stock options as directly owned by Stephen T. Zarrilli.

Q: Does the Form 4 for Globus Medical (GMED) show any stock sales by Stephen T. Zarrilli?

No stock sales are listed; the filing reports a grant of stock options coded as an acquisition (A) of derivative securities.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Globus Medical Inc. filed an insider trading report showing a new stock option grant to director Stephen T. Zarrilli. On January 21, 2026, he received options to buy 15,000 shares of Class A common stock at an exercise price of $94.15 per share. The grant was recorded at a price of $0 because it reflects an award, not a purchase in the market. These options are held directly and will vest on January 1, 2027, with an expiration date of January 21, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ZARRILLI STEPHEN T

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy Class A Common Stock)	15,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy Class A Common Stock) — 15,000 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/23/2026 - 04:51 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZARRILLI STEPHEN T

(Last)

(First)

(Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON

19403

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy Class A Common Stock)	$94.15	01/21/2026		A		15,000		⁽¹⁾	01/21/2036	Class A Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. These options were granted on January 21, 2026, and will vest on January 1, 2027.

	/s/ Kelly G. Huller, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Globus Medical (GMED) report for Stephen T. Zarrilli?

Globus Medical reported that director Stephen T. Zarrilli was granted a stock option for 15,000 shares of Class A common stock on January 21, 2026.

What is the exercise price of the new Globus Medical (GMED) stock options?

The granted stock options have an exercise price of $94.15 per share for Class A common stock.

When do Stephen T. Zarrilli’s Globus Medical (GMED) options vest and expire?

The options granted on January 21, 2026 will vest on January 1, 2027 and expire on January 21, 2036.

How many Globus Medical (GMED) derivative securities does Stephen T. Zarrilli hold after this transaction?

Following the reported transaction, Stephen T. Zarrilli beneficially owns 15,000 stock options for Class A common stock.

Is the Globus Medical (GMED) option grant reported as directly or indirectly owned?

The Form 4 shows the 15,000 stock options as directly owned by Stephen T. Zarrilli.

Does the Form 4 for Globus Medical (GMED) show any stock sales by Stephen T. Zarrilli?

No stock sales are listed; the filing reports a grant of stock options coded as an acquisition (A) of derivative securities.